These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 33634756)

  • 1. 1,3,4-Oxadiazole Containing Compounds As Therapeutic Targets For Cancer Therapy.
    Ahsan MJ
    Mini Rev Med Chem; 2022; 22(1):164-197. PubMed ID: 33634756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale Design, Synthesis, Cytotoxicity Evaluation, and Molecular Docking Studies of 1,3,4-oxadiazole Analogues.
    Ahsan MJ; Choupra A; Sharma RK; Jadav SS; Padmaja P; Hassan MZ; Al-Tamimi ABS; Geesi MH; Bakht MA
    Anticancer Agents Med Chem; 2018; 18(1):121-138. PubMed ID: 28425854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of novel HDAC8 inhibitory 2,5-disubstituted-1,3,4-oxadiazoles containing glycine and alanine hybrids with anti cancer activity.
    Pidugu VR; Yarla NS; Pedada SR; Kalle AM; Satya AK
    Bioorg Med Chem; 2016 Nov; 24(21):5611-5617. PubMed ID: 27665180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1,3,4-oxadiazole and its derivatives: A review on recent progress in anticancer activities.
    Vaidya A; Pathak D; Shah K
    Chem Biol Drug Des; 2021 Mar; 97(3):572-591. PubMed ID: 32946168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Groundbreaking Anticancer Activity of Highly Diversified Oxadiazole Scaffolds.
    Benassi A; Doria F; Pirota V
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33217987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, Synthesis, Anticancer Evaluation, and Molecular Docking Studies of Novel Benzoxazole Linked 1,3,4-Oxadiazoles.
    Bujji S; Kumar EP; Sivan SK; Manjunatha DH; Subhashini NJP
    Anticancer Agents Med Chem; 2022; 22(5):933-942. PubMed ID: 34229589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1,3,4-Oxadiazoles as Telomerase Inhibitor: Potential Anticancer Agents.
    Bajaj S; Roy PP; Singh J
    Anticancer Agents Med Chem; 2018 Feb; 17(14):1869-1883. PubMed ID: 28443517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and SAR studies of novel 1,2,4-oxadiazole-sulfonamide based compounds as potential anticancer agents for colorectal cancer therapy.
    Shamsi F; Hasan P; Queen A; Hussain A; Khan P; Zeya B; King HM; Rana S; Garrison J; Alajmi MF; Rizvi MMA; Zahid M; Imtaiyaz Hassan M; Abid M
    Bioorg Chem; 2020 May; 98():103754. PubMed ID: 32200329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic potential of oxadiazole or furadiazole containing compounds.
    Siwach A; Verma PK
    BMC Chem; 2020 Dec; 14(1):70. PubMed ID: 33372629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1,3,4-Oxadiazoles as Anticancer Agents: A Review.
    Kumar G; Kumar R; Mazumder A; Salahuddin ; Kumar U
    Recent Pat Anticancer Drug Discov; 2024; 19(3):257-267. PubMed ID: 37497702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Substituted oxadiazoles: a patent review (2010 - 2012).
    Zarghi A; Hajimahdi Z
    Expert Opin Ther Pat; 2013 Sep; 23(9):1209-32. PubMed ID: 23663160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxadiazoles as privileged motifs for promising anticancer leads: recent advances and future prospects.
    Khan I; Ibrar A; Abbas N
    Arch Pharm (Weinheim); 2014 Jan; 347(1):1-20. PubMed ID: 24265208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, cytotoxicity, and molecular docking of substituted 3-(2-methylbenzofuran-3-yl)-5-(phenoxymethyl)-1,2,4-oxadiazoles.
    Mokenapelli S; Thalari G; Vadiyaala N; Yerrabelli JR; Irlapati VK; Gorityala N; Sagurthi SR; Chitneni PR
    Arch Pharm (Weinheim); 2020 Jun; 353(6):e2000006. PubMed ID: 32309890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Furazans in Medicinal Chemistry.
    Mancini RS; Barden CJ; Weaver DF; Reed MA
    J Med Chem; 2021 Feb; 64(4):1786-1815. PubMed ID: 33569941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Medicinal Chemist's Perspective Towards Structure Activity Relationship of Heterocycle Based Anticancer Agents.
    Nehra B; Mathew B; Chawla PA
    Curr Top Med Chem; 2022; 22(6):493-528. PubMed ID: 35021975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and synthesis of 3,5-substituted 1,2,4-oxadiazoles as catalytic inhibitors of human DNA topoisomerase IIα.
    Loboda KB; Valjavec K; Štampar M; Wolber G; Žegura B; Filipič M; Dolenc MS; Perdih A
    Bioorg Chem; 2020 Jun; 99():103828. PubMed ID: 32315896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New oxadiazoles with selective-COX-2 and EGFR dual inhibitory activity: Design, synthesis, cytotoxicity evaluation and in silico studies.
    El-Sayed NA; Nour MS; Salem MA; Arafa RK
    Eur J Med Chem; 2019 Dec; 183():111693. PubMed ID: 31539778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and anticancer activities of novel 3,5-disubstituted-1,2,4-oxadiazoles.
    Kumar D; Patel G; Johnson EO; Shah K
    Bioorg Med Chem Lett; 2009 May; 19(10):2739-41. PubMed ID: 19376704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the Biological Activity of a Library of 1,2,5-Oxadiazole Derivatives Endowed With Antiproliferative Activity.
    Gelain A; Mori M; Meneghetti F; Porta F; Basile L; Marverti G; Asai A; Hyeraci M; García-Argáez AN; Via LD; Guccione S; Villa S
    Anticancer Res; 2019 Jan; 39(1):135-144. PubMed ID: 30591450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1,3,4-Oxadiazoles: An emerging scaffold to target growth factors, enzymes and kinases as anticancer agents.
    Bajaj S; Asati V; Singh J; Roy PP
    Eur J Med Chem; 2015 Jun; 97():124-41. PubMed ID: 25965776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.